Biomimetic nanoscale metal–organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy

Ni, Kaiyuan; Lan, Guangxu; Song, Yang; Hao, Ziyang; Lin, Wenbin

doi:10.1039/d0sc01949f

Cited by 89 publications

(90 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might be attributed to the porphin‐Fe centers of FeCe6 that mimic catalase to catalyze the conversion of endogenous H 2 O 2 to oxygen. [ 15 ]…”

Section: Resultsmentioning

confidence: 99%

“…Thus, to remove excess O 2 −• byproducts from normal tissues, Fe(Cl)‐chlorin e6 (FeCe6), which has superoxide dismutase‐mimicking activity [ 14 ] and catalase‐mimicking activity, was introduced into the system. [ 15 ] Simultaneously, as a photosensitizer derivative, FeCe6 can be easily degraded by light (photodegradation), which can be carefully utilized in this activatable system. [ 10,16 ]…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Harmless–Harmful Switchable and Uninterrupted Laccase‐Instructed Killer for Activatable Chemodynamic Therapy

Zhou

Liu

et al. 2021

Advanced Materials

View full text Add to dashboard Cite

Chemodynamic therapy (CDT) employs Fenton catalysts to kill cancer cells by converting intracellular hydrogen peroxide (H2O2) into hydroxyl radicals (OH•). Although many studies on H2O2 supplementation have been conducted to improve the therapeutic effect of CDT, few studies have focused on the application of superoxide radical (O2−•) in CDT, which may result in better efficacy. A major concern about O2−•‐mediated CDT is its tendency to induce serious oxidative damage to normal tissues, which may be addressed by using a degradable O2−• scavenger. Here, a harmless‐harmful switchable and uninterrupted laccase (LAC)‐instructed killer (HULK) is constructed, which is the first CDT agent accelerated by LAC‐instructed O2−• generation and possesses a harmless‐harmful switchable effect because of the photodegradation of the O2−• scavenger iron‐chlorin e6 (FeCe6). LAC‐instructed substrate oxidation effectively catalyzes O2−• production with the help of intracellular reduction, thereby promoting the conversion of Fe3+ to Fe2+, accelerating the generation of OH•, and inducing tumor cell apoptosis and necrosis. The introduced O2−• scavenger FeCe6 is quickly photodegraded during irradiation, while LAC‐instructed O2−• generation proceeds as before, resulting in activatable CDT. This work not only provides the first strategy for LAC‐instructed O2−• generation but also presents new insight into activatable CDT.

show abstract

“…This might be attributed to the porphin‐Fe centers of FeCe6 that mimic catalase to catalyze the conversion of endogenous H 2 O 2 to oxygen. [ 15 ]…”

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Harmless–Harmful Switchable and Uninterrupted Laccase‐Instructed Killer for Activatable Chemodynamic Therapy

Zhou

Liu

et al. 2021

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…In addition, they are also effective drug delivery platforms, owing to their intrinsic porous structures for the loading of drugs, and thus can be combined with other treatment modalities easily [ 117 ]. For example, Ni et al developed a biomimetic nMOF as a multifunction platform combining CDT, RT, radiodynamic therapy (RDT), and immunotherapy, to harnesses hypoxia for efficient tumor management ( Figure 6 ) [ 118 ]. Thus, we can expect to see more and more nMOF-based, combination hypoxic tumor therapies.…”

Section: Emerging Trends and Outlookmentioning

confidence: 99%

“… Schematic illustration of the mechanism of the nMOF as a multifunction platform for combining CDT, radiotherapy (RT), RDT, and immunotherapy for treating hypoxic tumors. Reproduced from [ 118 ]. Published by The Royal Society of Chemistry.…”

Section: Figurementioning

confidence: 99%

Nanomedicine-Based Strategies Assisting Photodynamic Therapy for Hypoxic Tumors: State-of-the-Art Approaches and Emerging Trends

Shih

Wang

et al. 2021

Biomedicines

View full text Add to dashboard Cite

Since the first clinical cancer treatment in 1978, photodynamic therapy (PDT) technologies have been largely improved and approved for clinical usage in various cancers. Due to the oxygen-dependent nature, the application of PDT is still limited by hypoxia in tumor tissues. Thus, the development of effective strategies for manipulating hypoxia and improving the effectiveness of PDT is one of the most important area in PDT field. Recently, emerging nanotechnology has benefitted progress in many areas, including PDT. In this review, after briefly introducing the mechanisms of PDT and hypoxia, as well as basic knowledge about nanomedicines, we will discuss the state of the art of nanomedicine-based approaches for assisting PDT for treating hypoxic tumors, mainly based on oxygen replenishing strategies and the oxygen dependency diminishing strategies. Among these strategies, we will emphasize emerging trends about the use of nanoscale metal–organic framework (nMOF) materials and the combination of PDT with immunotherapy. We further discuss future perspectives and challenges associated with these trends in both the aspects of mechanism and clinical translation.

show abstract

“…Nanoparticles wrapped in cell membranes bind to toxins and inflammatory mediator‐related substrates and can treat diseases such as bacterial infections and arthritis, [51] respectively. This treatment method is auspicious [52,53] .…”

Section: The Application Of Nanotechnology In Immune Checkpointsmentioning

confidence: 99%

Combined Application of Nanotechnology and Multiple Therapies with Tumor Immune Checkpoints

Sun

et al. 2020

ChemistrySelect

View full text Add to dashboard Cite

Tumor immunotherapy has received worldwide attention in cancer treatment owing to its apparent advantages, such as strong specificity and long curative effect. Among them, significant progress has been made on the immune checkpoint therapy in recent years. FDA approved PD‐L1/PD‐1 and CTLA‐4 immune checkpoint inhibitors have been broadly used in a variety of malignant tumors. However, because of the low response rate of immune checkpoint drugs, its clinical application has been greatly hindered. With the prominence of nanotechnology in bio‐medicine, the application of nanotechnology in immune checkpoints has also gained more and more attention. The combination of radiotherapy, chemotherapy, phototherapy, magnetic therapy and other methods in nanotechnology makes an excellent promoting effect in the treatment of immune checkpoint drugs. This article reviews the recent breakthroughs of nanotechnology in immune checkpoint blocking therapy, mainly focusing on the significant advantages of the combination of nanotechnology‐based immune checkpoint blocking therapy with other treatment methods. In addition, we also discussed the challenges in this area and pointed out some potential directions for future development.

show abstract

Biomimetic nanoscale metal–organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy

Abstract: Biomimetic Hf-DBP-Fe harnesses tumor hypoxia for cancer treatment via RT-RDT and CDT as well as synergistic combination with immune checkpoint blockade.

Cited by 89 publications

References 55 publications

A Harmless–Harmful Switchable and Uninterrupted Laccase‐Instructed Killer for Activatable Chemodynamic Therapy

A Harmless–Harmful Switchable and Uninterrupted Laccase‐Instructed Killer for Activatable Chemodynamic Therapy

Nanomedicine-Based Strategies Assisting Photodynamic Therapy for Hypoxic Tumors: State-of-the-Art Approaches and Emerging Trends

Combined Application of Nanotechnology and Multiple Therapies with Tumor Immune Checkpoints

Contact Info

Product

Resources

About